Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.

Saved in:

Bibliographic Details
Title:	Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Authors:	Zeller T; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Münnich IA; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Windisch R; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Hilger P; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Schewe DM; Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany., Humpe A; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Kellner C; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Source:	Frontiers in immunology [Front Immunol] 2023 Sep 13; Vol. 14, pp. 1240275. Date of Electronic Publication: 2023 Sep 13 (Print Publication: 2023).
Publication Type:	Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2023.1240275